Status: Recruiting
Β-Thalassemia Treatment with KL003 Cell Injection
This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major.
Participants needed: 41
Trial details
Phase: Phase 1, Phase 2Age: 3-35Biological sex: AllType: InterventionalSponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd.Updated: Mar 10, 2025Locations: 2
Eligibility criteria
Male or female age between 3-35 years; [+6]
Diagnosis of composite α thalassemia; [+13]